June 22, 2007
Soliris approved in Europe
Cheshire-based Alexion Pharmaceuticals Inc. has receieved approval from the European Commission top market its Soliris drug for the treatment of patients with paroxysmal nocturnal hemoglobinuria, a disabling and life-threatening blood disorder. Soliris, already approved in the United States, is the first therapy approved in Europe to treat the disease, the symptoms of which include severe anemia, disabling fatigue, recurrent pain, and intermittent episodes of dark colored urine. Alexion said it plans to begin reimbursement discussions with healthcare systems in major European countries immediately, and expects to introduce the drug in at least one country by the end of the year.
WBJ Web Partners
Most Recent
Most Recent
0 Comments